Inflammopharmacology

, Volume 25, Issue 4, pp 431–438 | Cite as

Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity

  • Mohammad A. Y. Alqudah
  • Sayer Al-azzam
  • Karem Alzoubi
  • Mohammad Alkhatatbeh
  • Khaldoon Alawneh
  • Ola Alazzeh
  • Bayan Ababneh
Original Article
  • 128 Downloads

Abstract

Background

Following the recommended guidelines is crucial for achieving patient remission in rheumatoid arthritis. The aim of this study was to assess the effect of proper drug utilization of antirheumatic drugs on disease activity and drug safety in Jordan.

Methods

In a retrospective cross-sectional study, patient’s demographics, clinical variables, drug regimens and side effects were recorded and the 28-joint disease activity scores were calculated. Patients were stratified into high, moderate, low disease activity or remission group.

Results

Around 80% of patients were using methotrexate which was under-dosed in 82% of them. Only 25% were using biologic drugs. Surprisingly, only 10% of patients had low disease activity and only 4% were in a remission state. Anaemia (32.3%) and mild renal impairment (27.6%) were the most common side effects.

Conclusions

The low frequency of well-controlled disease activity is interpreted by high occurrence of methotrexate underdosing and biologic agent underprescription. Implementing the role of a clinical pharmacist could have a real impact on tight control of such disease issues in Jordan.

Keywords

Rheumatoid arthritis DMARDs Biologic agents Disease activity Underdosing Underprescription Side effects 

Abbreviations

RA

Rheumatoid arthritis

DMARDs

Disease-modifying antirheumatic drugs

DAS28

The 28-joint disease activity score

ACR

American College of Rheumatology

EULAR

European League Against Rheumatism

MTX

Methotrexate

CRP

C-reactive protein

SC

Subcutaneous

TNF

Tumour-necrosis factor

Notes

Compliance with ethical standards

Conflict of interest

The authors have declared that no competing interests exist.

Funding

This work was supported by the Deanship of Research at Jordan University of Science and Technology. The contents of this publication are solely the responsibility of the authors and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  1. Ajeganova S, Andersson ML, Frostegard J, Hafstrom I (2013) Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 40:1958–1966CrossRefPubMedGoogle Scholar
  2. Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Obs Study J Rheumatol 29:1631–1638Google Scholar
  3. Aletaha D, Kapral T, Smolen JS (2003) Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62:482–486CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bakker MF, Jacobs JW, Verstappen SM, BIjlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(Suppl 3):iii56–60PubMedPubMedCentralGoogle Scholar
  5. Bianchi G, Caporali R, Todoerti M, Mattana P (2016) Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther 33:369–378CrossRefPubMedPubMedCentralGoogle Scholar
  6. Breedveld FC, Combe B (2011) Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 13(Suppl 1):S3PubMedPubMedCentralGoogle Scholar
  7. Calasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, Wulffraat NM (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15:R217CrossRefPubMedGoogle Scholar
  8. Davis LA, Polk B, Mann A, Wolff RK, Kerr GS, Reimold AM, Cannon GW, Mikuls TR, Caplan L (2014) Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. Clin Exp Rheumatol 32:324–332PubMedPubMedCentralGoogle Scholar
  9. Donahue KE, Jonas DE, Hansen RA et al (2012) Drug therapy for rheumatoid arthritis in adults: an update. Comparative effectiveness reviews, no 55. Agency for Healthcare Research and Quality, Rockville. https://www.ncbi.nlm.nih.gov/books/NBK97388/
  10. Duran J, Bockorny M, Dalal D, Lavalley M, Felson DT (2016) Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review. Ann Rheum Dis 75:1595–1598CrossRefPubMedPubMedCentralGoogle Scholar
  11. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, van Staa TP, Cooper C (2005) The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom general practice research database. Rheumatology (Oxford) 44:1394–1398CrossRefGoogle Scholar
  12. Gaujoux-Viala C, Nam J, Ramiro S, Landewe R, Buch MH, Smolen JS, Gossec L (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73:510–515CrossRefPubMedPubMedCentralGoogle Scholar
  13. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269CrossRefPubMedGoogle Scholar
  14. Liang KP (2013) Cardiovascular risk in rheumatoid arthritis (RA): does it matter if RA is diagnosed in early or late age? J Rheumatol 40:1945–1947CrossRefPubMedGoogle Scholar
  15. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74:415–421CrossRefPubMedGoogle Scholar
  16. Margaretten M, Julian L, Katz P, Yelin E (2011) Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol 6:617–623CrossRefPubMedPubMedCentralGoogle Scholar
  17. McInnes I (2009) Does practice mirror the evidence base in the treatment of rheumatoid arthritis? Clin Rheumatol 28:961–970CrossRefPubMedGoogle Scholar
  18. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62:1576–1582CrossRefPubMedPubMedCentralGoogle Scholar
  19. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73:516–528CrossRefPubMedGoogle Scholar
  20. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewe R (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73:529–535CrossRefPubMedGoogle Scholar
  21. Sarkis KS, Salvador MB, Pinheiro MM, Silva RG, Zerbini CA, Martini LA (2009) Association between osteoporosis and rheumatoid arthritis in women: a cross-sectional study. Sao Paulo Med J 127:216–222CrossRefPubMedGoogle Scholar
  22. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108CrossRefPubMedGoogle Scholar
  23. Singh JA, Saag KG, Bridges SL jr, AKL EA, Bannuru RR, Sullivan MC, Vaysbrot E, Mcnaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, ST Clair EW, Tindall E, Miller AS, Mcalindon T (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26PubMedGoogle Scholar
  24. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975CrossRefPubMedPubMedCentralGoogle Scholar
  25. Tanaka Y (2016) Current concepts in the management of rheumatoid arthritis. Korean J Intern Med 31:210–218CrossRefPubMedPubMedCentralGoogle Scholar
  26. Verschueren P, Westhovens R (2011) Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 50:1194–1200CrossRefGoogle Scholar
  27. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68:954–960CrossRefPubMedGoogle Scholar
  28. Wessels JA, De Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Mohammad A. Y. Alqudah
    • 1
  • Sayer Al-azzam
    • 1
  • Karem Alzoubi
    • 1
  • Mohammad Alkhatatbeh
    • 1
  • Khaldoon Alawneh
    • 2
  • Ola Alazzeh
    • 1
  • Bayan Ababneh
    • 1
  1. 1.Department of Clinical Pharmacy, Faculty of PharmacyJordan University of Science and TechnologyIrbidJordan
  2. 2.Department of Internal Medicine, Faculty of MedicineJordan University of Science and TechnologyIrbidJordan

Personalised recommendations